Court Rules FDA Must Restore Safeguards on Dangerous Abortion Pill That Hurts Women
Life News
Source: lifenews.com
📰 Risk Evaluation News
Page 22 - Risk Evaluation News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Risk Evaluation. Real-time updates on events, politics, business and more.
FDA Approves Elranatamab for Multiple Myeloma
Elranatamab is an off-the-shelf, B-cell maturation antigen CD3-targeted bispecific antibody.
Drug Administration Priority Review Breakthrough Therapy Designation Risk Evaluation Mitigation Strategy Multiple Myeloma
Source: medscape.com
Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT™ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma
/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...
Vojislav Vukovic Gerard Michel Ben Shamsian Exchange Commission Prnewswire Delcath Systems Inc Delcath Systems Inc
Source: prnewswire.com
FDA Approves Hepzato Kit for Metastatic Uveal Melanoma
The Hepzato Kit is a direct-to-liver therapy for patients with uveal melanoma with hepatic metastases.
Vojislav Vukovic Access Program Drug Administration National Comprehensive Cancer Network Hepzato Kit Delcath Systems
Source: curetoday.com
FDA Roundup: August 15, 2023
/PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced a...
United States Robertm Califf Healthywiser Uritest Igor Pogribny Pfizer Inc Arkansas Research Alliance
Source: prnewswire.com
FDA Roundup: August 11, 2023
/PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Thursday, the FDA issued an...
Theresa Mullin Genentech Inc Office Of Media Affairs Drug Administration Janssen Biotech Inc Outbreak Advisory
Source: prnewswire.com
U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted...
Source: prnewswire.com
Early, Appropriate Treatment for Postpartum Depression Can Help New Mothers
A variety of comorbid mood disorders often accompany this condition, including OCD and PTSD.
Source: pharmacytimes.com
J&J Broadens Scope in Multiple Myeloma, Winning FDA Approval for New Drug
Johnson & Johnson’s stable of multiple myeloma drugs has grown to five products with the FDA approval of Talvey. The bispecific antibody is the first in a new class of new drugs designed to go after the novel multiple myeloma target GPRC5D.
United States Mark Wildgust A Johnson American Society Of Hematology American Society Of Clinical Oncology American Society
Source: medcitynews.com
VANFLYTA® Now Available in U.S. for Patients with Newly Diagnosed FLT3-ITD Positive AML
Daiichi Sankyo today announced that VANFLYTA® is now available by prescription in the U.S. VANFLYTA is the first and only FLT3 inhibitor to be approved by the U.S. Food and Drug Administration ...
United States Daiichi Sankyo Dan Switzer American Cancer Society National Cancer Institute Daiichi Sankyo Inc
Source: marketscreener.com